Journal of Clinical Case Reports

A Case Report of Invasive Aspergillosis in a Patient Treated with Ruxolitinib

Abstract

Arvinder Cheema, Sajjad Ali* and Pranatharthi Chandrasekar

Invasive Aspergillosis (IA) is a severe opportunistic infection that typically affects immunocompromised patients. Ruxolitinib is a selective Janus kinase inhibitor which is used for steroid-refractory acute Graft-vs.-Host Disease (GVHD). Several case reports have described serious opportunistic infections in Ruxolitinib-treated Primary Myelofibrosis (PMF) patients but no routine antifungal prophylaxis is recommended in these patients. We present an interesting case of 77-year-old man with previous history of treated MDS several years ago currently on Ruxolitinib for GVHD who was found to have new cavitary lung lesion on routine imaging.